Pipecolic esters as minimized templates for proteasome inhibition

Area of Science:

• Biochemistry
• Pharmacology
• Structural Biology

Background:

• Allosteric enzyme regulators offer alternatives to competitive inhibitors, particularly for targets like the proteasome, crucial in cancer therapy.
• Existing proteasome inhibitors competitively bind the active site, leading to drug resistance.
• The search for non-competitive proteasome inhibitors is driven by the need to overcome resistance mechanisms.

Purpose of the Study:

• To identify novel proteasome-targeting pharmacophores.
• To develop a new class of non-competitive proteasome inhibitors.
• To elucidate the mechanism of action for a novel pipecolic ester derivative.

Main Methods:

• Structure-activity relationship studies based on rapamycin's binding domain.
• Biochemical assays to assess proteasome activity.
• Molecular modeling and atomic force microscopy imaging.
• Cell proliferation assays.

Main Results:

• A pipecolic ester derivative (compound 3) was identified as a novel proteasome inhibitor.
• Compound 3 exhibits low micromolar/high nanomolar efficacy against proteasome activity and cancer cell proliferation.
• Molecular modeling and imaging suggest compound 3 binds to intersubunit pockets in the proteasomal α ring, destabilizing the α face and gate.

Conclusions:

• The pipecolic ester template represents a new class of proteasome inhibitors with a distinct mechanism.
• This allosteric inhibition mechanism bypasses the resistance associated with competitive proteasome inhibitors.
• Compound 3 offers a promising new strategy for anti-cancer drug development targeting the proteasome.